On Wednesday, Boston Scientific Corporation (NYSE:BSX) released the results of the primary endpoint of the ACURATE IDE trial of ACURATE neo2 Aortic Valve System for patients with severe ...
Boston Scientific continues to work closely with the U.S. Food and Drug Administration on the regulatory strategy for approval of the ACURATE valve platform in the U.S. The ACURATE neo2 Aortic ...
atherectomy and stenting procedures in the lower extremity arteries Boston Scientific Corporation FilterWire EZ Embolic Protection System Filter Distal Indicated for use as a guidewire and EPS to ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
TCT 1018: Plaque Risk Is Directly Related to the Type and Number of Combined Vulnerability Features: Insights From a Pooled Patient Level Analysis From COMBINE FFR_OCT and PECTUS-OBS Studies Receive ...
Abu Dhabi, UAE — The use of a balloon guide catheter was associated with worse functional outcomes than the use of a conventional guide catheter in stroke patients with large vessel anterior ...
Boston Scientific Corporation (NYSE ... Mid-teens growth in Coronary Therapies was supported by the launch of the US AGENT ...
A collection of stories from our ongoing series, Field Guide to Boston. The series at wbur.org/fieldguide offers guides and public service journalism focused on how ...
Strong sales of a medical device to treat atrial fibrillation helped lift Boston Scientific’s top line last quarter, but an unexpected pause in an important clinical trial to expand the use of ...
Marlborough-based Boston Scientific increased its estimated net sales growth for 2024. Meanwhile, Thermo Fisher slightly raised its full-year adjusted earnings per share guidance. Boston ...
Good morning and welcome to the Boston Scientific Third Quarter 2024 Earnings ... Mid-teens growth in Coronary Therapies was supported by the launch of the US AGENT performance, continued global ...